Business
economy-US-ECONOMY-MILKEN
Pete Stavros, Co-Head of Global Private Equity at KKR, which did a $565 million dividend recap this year. (PATRICK FALLON / Getty Images)

Private equity is loading up companies with debt to juice dividends and delay their pain

Needing to make distributions to investors, PE firms have turned to one of their favorite tools: dividend recaps.

I have written, a few times now, about private equity’s cash flow problem: namely, PE as an industry is now raising more funding than they are distributing back to investors, so a lot of investor capital is tied up in portfolio companies that funds haven’t been able to sell.

The life cycle of a typical PE fund might be 10-12 years, in which capital is invested over the first half of the fund’s life, and investments are sold to return capital to limited partners over the second half. However, when funds find themselves unable to exit those positions, they have a problem: where do they get the money to pay investors?

The answer: junk bonds.

PE funds use a practice known as a “dividend recapitalization” to raise new debt in order to pay their investors a cash dividend (one example is 1-800 Contacts, a KKR portfolio company, taking out a $565 million loan earlier this year), and, according to The Wall Street Journal, dividend recaps through early August 2024 have hit $43 billion, up from $7.4 billion in the same period last year. 

Dividend recaps aren’t new, and the use of leveraged loans to distribute cash to investors exploded in 2020 and 2021 (according to the Journal piece, this year’s dividend recap payouts still lag behind 2021). However, in 2020 and 2021, debt was much cheaper as the Fed funds rate was close to 0%. With benchmark interest rates now sitting at 5%, the loans funding dividend recaps are more expensive to service, pressuring the portfolio companies. Additionally, despite the recent uptick in dividend recaps, capital is still being distributed to investors at an anemic rate of around 12%, down from 31.3% in 2021.

Personally, I don’t think this practice bodes well for private equity. As noted in my venture capital piece, “down rounds” are growing more popular in the venture space as startups can no longer justify their 2021 valuations, and, if they want to raise more capital, they’re going to have to take a haircut on their valuations. The same dynamic is in play in the more liquid stock market: you have to transact at market price, even if that price is below what you perceive to be the fair value.

Private equity valuations, however, tend to be subjective, and funds don’t want to mark down the value of their investments. Dividend recaps allow funds to maintain current valuations and avoid taking losses, but they’re just kicking the can down the road. Sooner or later, they will need to exit their positions, and when you do have to sell, your investment is only worth what someone else will pay for it. Loading that investment with pricey debt doesn’t make it a more attractive asset.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.